Xiamen Cancer Center, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
Xiamen Cancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, People's Republic of China.
Int J Surg. 2015 Nov;23(Pt A):147-51. doi: 10.1016/j.ijsu.2015.09.072. Epub 2015 Oct 9.
To assess the efficacy of different treatment modalities on the outcome of patients with low-grade endometrial stromal sarcoma (LG-ESS).
Patients with LG-ESS who received hysterectomy from March 1991 to December 2013 were retrospectively analyzed. The associations between clinicopathologic variables and disease free survival (DFS) were evaluated.
One hundred and fourteen patients met the eligibility requirements. All patients received hysterectomy as the main treatment, 17.5% (20/114) of patients received ovarian preservation, and 62.3% (71/114) of patients received lymphadenectomy. Fifty-six patients received chemotherapy, 36 patients received radiotherapy, and 11 patients received endocrine therapy. The median follow-up duration was 40 months. The 5-year and 10-year DFS rates were 91.8% and 77.4%, respectively. The 5-year and 10-year overall survival rates were 96.7% and 96.7%, respectively. Univariate analyses showed that there were no risk factors associated with DFS. Lymphadenectomy, lymph node status, ovarian preservation, chemotherapy, radiotherapy, and endocrine therapy had no significant effect on DFS.
Hysterectomy has been the mainstay of treatment for LG-ESS. The optimal treatment strategy in LG-ESS remains to be determined.
评估不同治疗方式对低级别子宫内膜间质肉瘤（LG-ESS）患者结局的影响。
回顾性分析 1991 年 3 月至 2013 年 12 月接受子宫切除术的 LG-ESS 患者。评估临床病理变量与无疾病生存（DFS）之间的关系。
114 名患者符合入选标准。所有患者均接受子宫切除术作为主要治疗方法，17.5%（20/114）的患者保留卵巢，62.3%（71/114）的患者行淋巴结切除术。56 例患者接受化疗，36 例患者接受放疗，11 例患者接受内分泌治疗。中位随访时间为 40 个月。5 年和 10 年 DFS 率分别为 91.8%和 77.4%。5 年和 10 年总生存率分别为 96.7%和 96.7%。单因素分析显示，DFS 无相关风险因素。淋巴结切除术、淋巴结状态、保留卵巢、化疗、放疗和内分泌治疗对 DFS 无显著影响。
子宫切除术一直是 LG-ESS 的主要治疗方法。LG-ESS 的最佳治疗策略仍有待确定。
